HIV-Negative Case of Talaromyces marneffei Pulmonary Infection with Liver Cirrhosis in China: A Case Report and Literature Review

References

• Vanittanakom N, Cooper CR, Fisher MC, Sirisanthana T. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev. 2006;19(1):95–110. doi:10.1128/CMR.19.1.95-110.2006
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhang J, Li X, et al. Penicillium marneffei infection: an emerging disease in mainland China. Mycopathologia. 2013;175(1–2):57–67. doi:10.1007/s11046-012-9577-0
   PubMed Web of Science ®Google Scholar
• Yilmaz N, Visagie CM, Houbraken J, Frisvad JC, Samson RA. Polyphasic taxonomy of the genus Talaromyces. Stud Mycol. 2014;78:175–341. doi:10.1016/j.simyco.2014.08.001
   PubMed Web of Science ®Google Scholar
• Capponi M, Segretain G, Sureau P. Pénicillose de Rhizomys sinensis [Penicillosis from Rhizomys sinensis]. Bull Soc Pathol Exot Filiales. 1956;49(3):418–421. French.
   PubMedGoogle Scholar
• Wang Y, Mo X, Zhang J, et al. Clinical features of Talaromyces marneffei infection in HIV-positive and HIV-negative individuals: a retrospective study in southern China. Med Mycol. 2023;61(8). doi:10.1093/mmy/myad083
   Web of Science ®Google Scholar
• Qiu Y, Liu AL, Huang J, et al. Comparison of the clinical features of HIV-positive and HIV-negative hosts infected with Talaromyces marneffei: a multicenter, retrospective study. Int J Infect Dis. 2023;132:93–98. doi:10.1016/j.ijid.2023.04.398
   PubMed Web of Science ®Google Scholar
• Yu Q, Wei M, Xiao R, et al. Clinical characteristics, course, and long-term outcomes in patients with talaromyces marneffei infection: a 10-year retrospective cohort study. Infect Dis Ther. 2023;12(5):1283–1297. doi:10.1007/s40121-023-00801-5
   PubMed Web of Science ®Google Scholar
• Qiu Y, Pan M, Zhang J, et al. Two unusual cases of human immunodeficiency virus-negative patients with talaromyces marneffei infection. Am J Trop Med Hyg. 2016;95(2):426–430. doi:10.4269/ajtmh.15-0789
   PubMed Web of Science ®Google Scholar
• Zhang J, Huang X, Zhang X, et al. Coinfection of disseminated Talaromyces marneffei and Mycobacteria kansasii in a patient with papillary thyroid cancer: a case report. Medicine. 2017;96(52):e9072. doi:10.1097/MD.0000000000009072
   PubMed Web of Science ®Google Scholar
• Yu X, Miao K, Zhou C, et al. T. marneffei infection complications in an HIV-negative patient with pre-existing pulmonary sarcoidosis: a rare case report. BMC Infect Dis. 2018;18(1):390. doi:10.1186/s12879-018-3290-7
   PubMedGoogle Scholar
• Zhu YM, Ai JW, Xu B, et al. Rapid and precise diagnosis of disseminated T. Marneffei infection assisted by high-throughput sequencing of multifarious specimens in a HIV-negative patient: a case report. BMC Infect Dis. 2018;18(1):379. doi:10.1186/s12879-018-3276-5
   PubMedGoogle Scholar
• Lin F, Qiu Y, Zeng W, Liang Y, Zhang J. Talaromyces marneffei infection in a lung cancer patient: a rare case report. BMC Infect Dis. 2019;19(1):336. doi:10.1186/s12879-019-3968-5
   PubMedGoogle Scholar
• Chen Y. A Talaromyces marneffei infection with osteolytic lesions in an HIV-negative patient at non-endemic areas: a case report. SAGE Open Med Case Rep. 2020;8:2050313x20938242. doi:10.1177/2050313X20938242
   Web of Science ®Google Scholar
• Zhang W, Ye J, Qiu C, et al. Rapid and precise diagnosis of T. marneffei pulmonary infection in a HIV-negative patient with autosomal-dominant STAT3 mutation: a case report. Ther Adv Respir Dis. 2020;14:1753466620929225. doi:10.1177/1753466620929225
   Web of Science ®Google Scholar
• Chen D, Chang C, Chen M, et al. Unusual disseminated Talaromyces marneffei infection mimicking lymphoma in a non-immunosuppressed patient in East China: a case report and review of the literature. BMC Infect Dis. 2020;20(1):800. doi:10.1186/s12879-020-05526-1
   PubMed Web of Science ®Google Scholar
• Lin F, Yang Z, Qiu Y, Zeng W, Liu G, Zhang J. Talaromyces marneffei infection in lung cancer patients with positive AIGAs: a rare case report. Infect Drug Resist. 2021;14:5005–5013. doi:10.2147/IDR.S340694
   PubMed Web of Science ®Google Scholar
• Shen Q, Sheng L, Zhou J. HIV-negative case of Talaromyces marneffei pulmonary infection with a TSC2 mutation. J Int Med Res. 2021;49(5):3000605211016761. doi:10.1177/03000605211016761
   Web of Science ®Google Scholar
• Huang H, Deng J, Qin C, Zhou J, Duan M. Disseminated Coinfection by Mycobacterium fortuitum and Talaromyces marneffei in a Non-HIV Case. Infect Drug Resist. 2021;14:3619–3625. doi:10.2147/IDR.S316881
   PubMed Web of Science ®Google Scholar
• Yang Z, Zeng W, Qiu Y, Liu G, Zhang J. Nodular sclerosing Hodgkin lymphoma combined with disseminated talaromyces marneffei infection: a case report. Infect Drug Resist. 2021;14:5671–5678. doi:10.2147/IDR.S340192
   PubMed Web of Science ®Google Scholar
• Liu W, Xu J, Lin B, et al. Pneumonia caused by Talaromyces marneffei in an epidermal growth factor receptor (EGFR) mutation-positive advanced lung adenocarcinoma patient: a case report. Ann Palliat Med. 2021;10(1):759–766. doi:10.21037/apm-20-2137
   PubMed Web of Science ®Google Scholar
• Zhan Y, Lu C, Li S, et al. Successful management of mixed mycosis in HIV-negative patients with different immune status: a case series report. Front Cell Infect Microbiol. 2022;12:851891. doi:10.3389/fcimb.2022.851891
   PubMed Web of Science ®Google Scholar
• Chen L, Zhang M, Guo W, et al. Case report: acute Talaromyces marneffei mediastinitis in an HIV-negative patient. Front Microbiol. 2022;13:1045660. doi:10.3389/fmicb.2022.1045660
   PubMed Web of Science ®Google Scholar
• Qiu Y, Pan M, Yang Z, et al. Talaromyces marneffei and Mycobacterium tuberculosis co-infection in a patient with high titer anti-interferon-γ autoantibodies: a case report. BMC Infect Dis. 2022;22(1):98. doi:10.1186/s12879-021-07015-5
   PubMed Web of Science ®Google Scholar
• Cai DH, Wang J, Fang XL. Successful treatment of Talaromyces marneffei pneumonia in a HIV-negative renal transplantation recipient: a case report. Medicin. 2022;101(40):e30958. doi:10.1097/MD.0000000000030958
   Google Scholar
• Du R, Feng Y, Mao H. Case report: diagnosis of Talaromyces marneffei infection in an HIV-negative patient with septic shock and high-titer anti-interferon gamma autoantibodies by metagenomic next-generation sequencing. Front Cell Infect Microbiol. 2023;13:1163846. doi:10.3389/fcimb.2023.1163846
   PubMed Web of Science ®Google Scholar
• Singh MK, Borson S, Lei V, Molloy R, Weng B, Sutjita M. Rare cases of Talaromyces pneumonia in individuals with underlying cancer and no travel to endemic areas. IDCases. 2023; 33:e01831.
   PubMed Web of Science ®Google Scholar
• Chen Z, Luo XL, Li WQ, Deng ZP. Talaromyces marneffei infection in an HIV-negative patient in a non-endemic area: a case report and literature review. Clin Lab. 2023;69(9). doi:10.7754/Clin.Lab.2023.230334
   Web of Science ®Google Scholar
• Yang H, Liu M, Xu N, et al. Disseminated Talaromyces marneffei infection associated with haemophagocytic syndrome in an HIV-negative patient in northern China: a case report. BMC Infect Dis. 2024;24(1):63. doi:10.1186/s12879-023-08953-y
   PubMed Web of Science ®Google Scholar
• Shih HP, Ding JY, Yeh CF, Chi CY, Ku CL. Anti-interferon-γ autoantibody-associated immunodeficiency. Curr Opin Immunol. 2021;72:206–214. doi:10.1016/j.coi.2021.05.007
   PubMed Web of Science ®Google Scholar
• Li Z, Yang J, Qiu Y, et al. Disseminated talaromyces marneffei infection With STAT3-Hyper-IgE syndrome: a case series and literature review. Open Forum Infect Dis. 2023;10(4):ofac614. doi:10.1093/ofid/ofac614
   PubMed Web of Science ®Google Scholar
• Hillmer EJ, Zhang H, Li HS, Watowich SS. STAT3 signaling in immunity. Cytokine Growth Factor Rev. 2016;31:1–15. doi:10.1016/j.cytogfr.2016.05.001
   PubMed Web of Science ®Google Scholar
• Tsilifis C, Freeman AF, Gennery AR. STAT3 Hyper-IgE syndrome-an update and unanswered questions. J Clin Immunol. 2021;41(5):864–880. doi:10.1007/s10875-021-01051-1
   PubMed Web of Science ®Google Scholar
• Andrianopoulos A. Laboratory maintenance and growth of talaromyces marneffei. Curr Protoc Microbiol. 2020;56(1):e97. doi:10.1002/cpmc.97
   PubMedGoogle Scholar
• He L, Mei X, Lu S, et al. Talaromyces marneffei infection in non-HIV-infected patients in mainland China. Mycoses. 2021;64(10):1170–1176. doi:10.1111/myc.13295
   PubMed Web of Science ®Google Scholar
• Irvine KM, Ratnasekera I, Powell EE, Hume DA. Causes and consequences of innate immune dysfunction in cirrhosis. Front Immunol. 2019;10:293. doi:10.3389/fimmu.2019.00293
   PubMed Web of Science ®Google Scholar
• Li TY, Yang Y, Zhou G, Tu ZK. Immune suppression in chronic hepatitis B infection associated liver disease: a review. World J Gastroenterol. 2019;25(27):3527–3537. doi:10.3748/wjg.v25.i27.3527
   PubMed Web of Science ®Google Scholar
• Tranah TH, Edwards LA, Schnabl B, Shawcross DL. Targeting the gut-liver-immune axis to treat cirrhosis. Gut. 2021;70(5):982–994. doi:10.1136/gutjnl-2020-320786
   PubMed Web of Science ®Google Scholar